Oramed Pharmaceuticals (ORMP)
(Delayed Data from NSDQ)
$2.44 USD
-0.03 (-1.02%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $2.43 -0.01 (-0.21%) 7:40 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ORMP 2.44 -0.03(-1.02%)
Will ORMP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ORMP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ORMP
Scilex announces repayment of balance of convertible debentures
Oramed Pharmaceuticals Welcomes New Audit Committee Chair
Oramed Pharmaceuticals Updates Stock Sale Strategies and Partners
ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q4 2023
Oramed Pharmaceuticals CEO Updates Shareholders on Strategy